Find an abstract and a link to all the publications produced by Nordic Bioscience
The therapeutic goal of increasing bone mass by co-treatment of parathyroid hormone (PTH) and an osteoclast inhibitor has been complicated by the undefined contribution of osteoclasts to the anabolic activity of PTH. To determine whether active osteoclasts are required at the time of PTH administrat...
June 6, 2010
Journal:
Bone
Author:
Gooi JH, Pompolo S, Karsdal MA, Kulkarni NH, Kalajzic I, McAhren SH, Han B, Onyia JE, Ho PW, Walsh NC, Chia LY, Quinn JM, Martin TJ, Sims NA
The therapeutic goal of increasing bone mass by co-treatment of parathyroid hormone (PTH) and an osteoclast inhibitor has been complicated by the undefined contribution of osteoclasts to the anabolic activity of PTH. To determine whether active osteoclasts are required at the time of PTH administrat...
June 6, 2010
Journal:
Bone
Author:
Gooi JH, Pompolo S, Karsdal MA, Kulkarni NH, Kalajzic I, McAhren SH, Han B, Onyia JE, Ho PW, Walsh NC, Chia LY, Quinn JM, Martin TJ, Sims NA
Since parathyroid hormone (PTH) is the only proven anabolic therapy for bone, it becomes the benchmark by which new treatments will be evaluated. The anabolic effect of PTH is dependent upon intermittent administration, but when an elevated PTH level is maintained even for a few hours it initiates p...
April 10, 2006
Journal:
Ann N Y Acad Sci
Author:
Martin TJ, Quinn JM, Gillespie MT, Ng KW, Sims NA, Karsdal MA
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
We use cookies on our site to enable essential services and functionalities, and collect data in regards to visitor information to provide the best possible experience. By using our website, you agree to our Privacy Policy and our cookies usage. Cookie Policy Privacy Statement
